Details of the Drug Combination

General Information of Drug Combination (ID: DC65KCR)

Drug Combination Name

ABT-199 JQ1

Indication

Disease Entry	Status	REF
Diffuse intrinsic pontine glioma	Investigative	[1]

Component Drugs

ABT-199 DM2BLMT

JQ1 DM3XQDH

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: DIPG25

Zero Interaction Potency (ZIP) Score: 11.214

Bliss Independence Score: 9.525

Loewe Additivity Score: 11.373

LHighest Single Agent (HSA) Score: 18.893

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of ABT-199

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 3	[2]

Indication(s) of JQ1

Disease Entry	ICD 11	Status	REF
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[3]

JQ1 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
HUMAN bromodomain-containing protein 2 (BRD2)	TTNISW6	BRD2_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Clinical pipeline report, company report or official report of Abbott Laboratories.
3	Uncovering the Role of BRD2 in COVID-19. 2020-03-19